Previous 10 | Next 10 |
2024-05-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...
2024-05-09 18:15:11 ET Image source: The Motley Fool. GoodRx (NASDAQ: GDRX) Q1 2024 Earnings Call May 09, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: GoodRx (GDRX) Q1 2024 Earnings Call Transcript
2024-05-09 17:15:25 ET GoodRx Holdings, Inc. (GDRX) Q1 2024 Earnings Conference Call May 09, 2024 08:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Michael Cherny - ...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-09 06:08:47 ET More on GoodRx Holdings GoodRx Holdings: Large TAM Continues To Support Growth R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space Seeking Alpha's Quant Rating on GoodRx Holdings Read the full article on Seeking Al...
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Reven...
2024-05-08 14:08:42 ET More on GoodRx Holdings GoodRx Holdings: Large TAM Continues To Support Growth GoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call Transcript R1 RCM, Health Catalyst downgraded as KeyBanc reviews health-tech space Wells Fargo upgrades Go...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In GoodRx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 7, 2024) - Faruqi & Faruqi, LLP, a leading national secu...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In GoodRx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 5, 2024) - Faruqi & Faruqi, LLP, a leading national secu...
News, Short Squeeze, Breakout and More Instantly...
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® PR Newswire First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and S...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management ...
Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the ...